Endometrial Cancer

Collectively, our findings reveal that SNRPD3 serves as an oncogenic splicing factor that promotes EC proliferation and metastasis by regulating SREBF1 mRNA splicing. Given its potent antitumor efficacy in preclinical PDX models, ASO-targeted SNRPD3 may represent a promising therapeutic strategy for endometrial cancer.

P=N/A, N=1715, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

P1, N=70, Recruiting, Compass Therapeutics | Not yet recruiting --> Recruiting

P2/3, N=98, Not yet recruiting, Genmab A/S

ERα36 is highly expressed in DIE tissues and exhibits good diagnostic performance with high sensitivity and specificity. These findings suggest that ERα36 may serve as a novel tissue-level biomarker for DIE, representing a potential target for future therapeutic strategies.

At the same time, growing evidence underscores the importance of crosstalk between hormonal dysregulation and immune mechanisms within the tumour microenvironment, a relationship that profoundly influences tumour behaviour and therapeutic response. In this review, we present a comprehensive overview of the current state of EC management and emerging therapeutic directions, with particular emphasis on treatment options available in Poland, the authors' country of origin.

Taken together, this study identifies ATM c.7374_7375insAlu as a novel FC founder PV that contributes to PC and BC predisposition. Improving carrier detection may identify at-risk relatives who may benefit from cancer-directed surveillance.

PRAME nuclear expression is highly sensitive and specific for carcinomas of endometrial and tubo-ovarian origin, with minimal expression in endocervical adenocarcinomas and ovarian mucinous carcinomas. PRAME IHC may be an adjunct tool to determine the site of origin in gynecologic carcinomas of uncertain primary.

Our findings establish CENPA as a critical oncogenic driver in EC that functions by stabilizing YY1 to promote metabolic reprogramming. The CENPA-YY1 axis may represent a potential therapeutic target for EC.

A direct correlation between arginase-1+ ILC2s and monocytic myeloid-derived suppressor cells suggests a synergistic role in endometrial carcinoma progression.ConclusionOur study indicates that the collaborative effects of ILC2s and myeloid-derived suppressor cells promote type II immunity and may contribute to the progression of endometrial carcinoma. Elevated levels of arginase-1+ ILC2s and monocytic myeloid-derived suppressor cells are associated with a poor prognosis in patients with endometrial carcinoma.

Transcriptomic phenotypes complement molecular subtypes in high-grade EC, enhancing biological resolution and capturing clinically relevant heterogeneity. These results underscore persistent challenges of current molecular classification approaches, supporting the need for integrative strategies in high-grade disease.